ISEE IVERIC bio Inc.

6.92
-0.18  -3%
Previous Close 7.1
Open 7.11
Price To Book 3.7
Market Cap 288,099,038
Shares 41,632,809
Volume 209,259
Short Ratio
Av. Daily Volume 1,024,553
Stock charts supplied by TradingView

NewsSee all news

  1. IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura® in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

     - On-Track for First Patient Enrollment in 1Q 2020– -Company to Host R&D Symposium for Investors/Analysts on Tuesday January 14, 2020 in San Francisco, CA from 6:30 to 8:00 am (Pacific Time) - IVERIC bio, Inc.

  2. IVERIC bio to Host an R&D Investor Symposium on Tuesday, January 14, 2020 in San Francisco, CA

    - Featuring Zimura® Pivotal Program in Geographic Atrophy, Including the Design of the Second Pivotal Trial in GA - - Live Webcast to Begin at 6:30 a.m. Pacific Time - IVERIC bio, Inc. (NASDAQ:ISEE) today announced

  3. IVERIC bio to Present at the 38th Annual J.P. Morgan Healthcare Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the 38th Annual J.P. Morgan Healthcare Conference

  4. IVERIC bio, Inc. Announces Pricing of Public Offering of Common Stock

    IVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $4.000 per share and, to certain

  5. IVERIC bio, Inc. Announces Proposed Offering of Common Stock

    IVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof).

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due 2H 2020.
Zimura
Autosomal Recessive Stargardt Disease
Phase 2a top-line data released November 12, 2018 noted that treatment was generally well tolerated.
Zimura
Wet age-related macular degeneration (Wet-AMD)
Phase 3 data released December 12, 2016 - primary endpoint not met. Data from third trial released August 14, 2017- primary endpoint not met.
Fovista
Wet age-related macular degeneration (Wet-AMD)
Phase 2b data released October 28, 2019 met primary endpoint. Phase 3 trial to commence 1Q 2020.
Zimura
Geographic atrophy
Phase 1/2 trial to be initiated 2H 2020.
IC-100
Rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP)
Phase 1/2 trial to be initiated 1H 2021.
IC-200
BEST1 related retinal diseases

Latest News

  1. IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura® in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

     - On-Track for First Patient Enrollment in 1Q 2020– -Company to Host R&D Symposium for Investors/Analysts on Tuesday January 14, 2020 in San Francisco, CA from 6:30 to 8:00 am (Pacific Time) - IVERIC bio, Inc.

  2. IVERIC bio to Host an R&D Investor Symposium on Tuesday, January 14, 2020 in San Francisco, CA

    - Featuring Zimura® Pivotal Program in Geographic Atrophy, Including the Design of the Second Pivotal Trial in GA - - Live Webcast to Begin at 6:30 a.m. Pacific Time - IVERIC bio, Inc. (NASDAQ:ISEE) today announced

  3. IVERIC bio to Present at the 38th Annual J.P. Morgan Healthcare Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the 38th Annual J.P. Morgan Healthcare Conference

  4. IVERIC bio, Inc. Announces Pricing of Public Offering of Common Stock

    IVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $4.000 per share and, to certain

  5. IVERIC bio, Inc. Announces Proposed Offering of Common Stock

    IVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof).

  6. IVERIC bio to Present at Evercore ISI 2nd Annual HealthCONx Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Evercore ISI 2nd Annual HealthCONx Conference

  7. IVERIC bio Appoints Guangping Gao, PhD, Internationally Recognized Gene Therapy Pioneer as Chief Strategist, Gene Therapy

    - Globally Recognized Innovator Played a Key Role in the Discovery and Vector Development of New AAV Serotypes - IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Guangping Gao, PhD, as Chief

  8. IVERIC bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019

    - Live Webcast to Begin at 8:00 a.m. Eastern Time - IVERIC bio, Inc. (NASDAQ:ISEE) today announced details for its previously announced Zimura® R&D Symposium for Investors being held in New York, NY on Wednesday,

  9. IVERIC bio Reports Third Quarter 2019 Operational Highlights and Financial Results

    - Conference Call and Webcast Today, November 12, 2019, at 8:00 a.m. ET - IVERIC bio, Inc. (NASDAQ:ISEE) today provided further details of the recently announced clinical trial results for the Company's

  10. IVERIC bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled

    - Company Plans to Use Previously Announced Positive Zimura Clinical Trial as One of Two Pivotal Trials - - Zimura R&D Symposium for Investors/Analysts to be Held on November 20, 2019 - - Conference Call and

  11. IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on November 1, 2019, the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of the Company's common stock. In addition, on

  12. IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019

    - Company to Host a Zimura® R&D Symposium for Investors on November 20, 2019 - IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its third quarter 2019 financial and operating results on Tuesday,

  13. IVERIC bio's Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    - Overall Data Suggest a Dose Response Relationship Across Treatment Groups - - Conference Call and Webcast Today, October 28, 2019 at 8:00 a.m. ET - IVERIC bio, Inc. (NASDAQ:ISEE) today announced initial topline

  14. IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Chardan Capital Markets 3rd Annual Genetic

  15. IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Kourous A. Rezaei, MD, Chief Medical Officer of IVERIC bio, will present an overview of the Company at the Ladenburg Thalmann 2019 Healthcare Conference in New York on